•Psoriasis (PsO) is an immune mediated chronic inflammatory disease, which has significant impact on health related quality of life (HRQoL). Disease severity and assessment of patient reported outcomes (PROs) has become increasingly important for defining effective treatment options. •The objective of this study is to examine the association between disease severity measured by Psoriasis Area and Severity Index (PASI) and patient reported outcomes (PROs) at enrollment in the Corrona Psoriasis Registry, a prospective observational cohort of PsO patients.
Impact of Psoriasis Area and Severity Index (PASI) on patient reported outcomes in patients with psoriasis: Results from the Corrona Psoriasis Registry
Secukinumab Patient-Reported Outcomes in the Corrona Psoriasis Registry
•Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, was approved for moderate to severe plaque psoriasis in 2015 •The Corrona Psoriasis Registry was launched in April 2015 in collaboration with the National Psoriasis Foundation (NPF) to study the comparative safety of approved systemic psoriasis therapies in a real world setting •Psoriasis can have significant burden on quality of life and this presentation describes patient reported outcomes (PROs) at enrollment in patients treated with secukinumab compared with other systemic treatments